Babson Diagnostics Recognized for Achieving Highest Standards of Quality and Patient Safety for Laboratory Medicine

2024-01-24

Babson Laboratory receives accreditation from the College of American Pathologists AUSTIN, Texas--(BUSINESS WIRE)-- Babson Diagnostics, a science-first health care technology company, today announced its new, highly automated microsample laboratory has been awarded accreditation by the College of American Pathologists (CAP) based on the results of a recent on-site inspection. The global recognition is a critical step on Babson’s path to commercially launch the BetterWay™ blood testing service at retail pharmacies in Texas this year. BetterWay makes blood testing easier and more accessible by using only a pea-sized amount of blood collected from a fingertip to produce medically accurate results clinicians and patients can trust. Babson will analyze the microsamples at its clinical lab, which opened last year inside its new corporate headquarters. This was the first time the new lab had gone through the CAP review process. Babson’s previous lab in Austin received CAP accreditation in 2020 and 2022. “We thank the Accreditation Committee of the College of American Pathologists for its thorough review,” said James Jacobson, Babson’s vice president of clinical affairs. “Receiving accreditation reflects our commitment to a rigorous scientific evaluation of our innovative analysis technologies before commercialization of BetterWay.” During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. These reviews help verify activities and reflect the most recent best practices. Babson’s compliance means the company is meeting the highest standards of quality and patient safety in its laboratory practices. The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program. “On our journey to make routine blood testing easier, more accessible, and less invasive, we are innovating with integrity,” said David Stein, Babson's chief executive officer. “Achieving accreditation is another step in our plan to show that BetterWay meets high scientific standards and produces quality diagnostic results that patients and clinicians can rely on.” About the College of American Pathologists As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care. About Babson Diagnostics Babson Diagnostics is a science-first healthcare technology company reimagining the entire diagnostic blood testing experience. Babson's mission is to make routine blood testing less invasive, more convenient, and affordable, empowering people to take charge of their health. Babson is preparing for the commercial launch of BetterWay™ blood testing, a first-of-its-kind ecosystem designed for primary care and family medicine, supporting annual exams, chronic condition monitoring, and screenings. BetterWay expands access to blood testing by using a pea-sized amount of blood collected from a fingertip by trained healthcare professionals in convenient locations without the need for a phlebotomist. BetterWay covers the most ordered tests and produces high-quality results equivalent to traditional methods of blood testing that require much more sample volume. The company has received key patents in the United States, European Union, and China related to its unique end-to-end technological ecosystem and the ability to maximize the clinical utility of microsamples of blood collected from a fingertip. In addition, Babson has fully validated a broad set of miniaturized assays that are ready for commercial use in its CLIA-certified laboratory. Babson, based in Austin, Texas, is led by individuals with deep experience in healthcare, diagnostics, engineering, and laboratory technologies. The company is named in honor of Art Babson, whose legacy of scientific innovation and excellence is the foundation on which the company is built. For more information, please visit .